Systemic lupus erythematosus and malignancies: a review article

Basile Tessier Cloutier; Ann E Clarke; Rosalind Ramsey-Goldman; Caroline Gordon; James E Hansen; Sasha Bernatsky

doi:10.1016/j.rdc.2014.04.005

Systemic lupus erythematosus and malignancies: a review article

Basile Tessier Cloutier, Ann E Clarke, Rosalind Ramsey-Goldman, Caroline Gordon, James E Hansen, Sasha Bernatsky

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

The systemic lupus erythematosus (SLE) population has a unique cancer risk profile. This article presents the most recent data on risk of cancer in lupus and discusses possible contributing factors. The risk of lymphoma is particularly increased in SLE and may be mediated by immunosuppressive medication. Lung cancer risk is also increased in SLE. There is a high rate of cervical dysplasia in women with SLE. A similar pathophysiology could be responsible for the trend seen in vulvovaginal and hepatic carcinomas. There is a decreased risk in SLE for some hormone-sensitive cancers, but the cause of this remains unclear.

Original language	English
Pages (from-to)	497-506, viii
Journal	Rheumatic Diseases Clinics of North America
Volume	40
Issue number	3
DOIs	https://doi.org/10.1016/j.rdc.2014.04.005
Publication status	Published - Aug 2014

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.rdc.2014.04.005

Cite this

@article{329263894e5f4038a4bd543ab1971ac5,

title = "Systemic lupus erythematosus and malignancies: a review article",

abstract = "The systemic lupus erythematosus (SLE) population has a unique cancer risk profile. This article presents the most recent data on risk of cancer in lupus and discusses possible contributing factors. The risk of lymphoma is particularly increased in SLE and may be mediated by immunosuppressive medication. Lung cancer risk is also increased in SLE. There is a high rate of cervical dysplasia in women with SLE. A similar pathophysiology could be responsible for the trend seen in vulvovaginal and hepatic carcinomas. There is a decreased risk in SLE for some hormone-sensitive cancers, but the cause of this remains unclear.",

author = "Cloutier, {Basile Tessier} and Clarke, {Ann E} and Rosalind Ramsey-Goldman and Caroline Gordon and Hansen, {James E} and Sasha Bernatsky",

year = "2014",

month = aug,

doi = "10.1016/j.rdc.2014.04.005",

language = "English",

volume = "40",

pages = "497--506, viii",

journal = "Rheumatic Diseases Clinics of North America",

issn = "0889-857X",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Systemic lupus erythematosus and malignancies

T2 - a review article

AU - Cloutier, Basile Tessier

AU - Clarke, Ann E

AU - Ramsey-Goldman, Rosalind

AU - Gordon, Caroline

AU - Hansen, James E

AU - Bernatsky, Sasha

PY - 2014/8

Y1 - 2014/8

N2 - The systemic lupus erythematosus (SLE) population has a unique cancer risk profile. This article presents the most recent data on risk of cancer in lupus and discusses possible contributing factors. The risk of lymphoma is particularly increased in SLE and may be mediated by immunosuppressive medication. Lung cancer risk is also increased in SLE. There is a high rate of cervical dysplasia in women with SLE. A similar pathophysiology could be responsible for the trend seen in vulvovaginal and hepatic carcinomas. There is a decreased risk in SLE for some hormone-sensitive cancers, but the cause of this remains unclear.

AB - The systemic lupus erythematosus (SLE) population has a unique cancer risk profile. This article presents the most recent data on risk of cancer in lupus and discusses possible contributing factors. The risk of lymphoma is particularly increased in SLE and may be mediated by immunosuppressive medication. Lung cancer risk is also increased in SLE. There is a high rate of cervical dysplasia in women with SLE. A similar pathophysiology could be responsible for the trend seen in vulvovaginal and hepatic carcinomas. There is a decreased risk in SLE for some hormone-sensitive cancers, but the cause of this remains unclear.

U2 - 10.1016/j.rdc.2014.04.005

DO - 10.1016/j.rdc.2014.04.005

M3 - Article

C2 - 25034158

SN - 0889-857X

VL - 40

SP - 497-506, viii

JO - Rheumatic Diseases Clinics of North America

JF - Rheumatic Diseases Clinics of North America

IS - 3

ER -

Systemic lupus erythematosus and malignancies: a review article

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this